

VITAMIN D RECEPTORS GENES POLYMORPHISMS AND OXIDATIVE DNA DAMAGE AMONG KURD PATIENTS WITH TYPE 2 DIABETES, KURDISTAN REGION (IRAQ)

ARDAWAN F. ALI, BSC, MSC*
DHIA J. AL-TIMIMI, BSC (PHARM), MPHIL, PHD**

Submitted 07 December 2018; accepted 7 June 2019

ABSTRACT

Background: Although the relationship between vitamin D deficiency and oxidative DNA damage has been previously reported, few studies have examined vitamin D receptor (VDR) gene polymorphisms for association with the risk of DNA damage. This study aimed to identify vitamin D receptor genotypes in patients with type 2 diabetes and healthy subjects, as well as identify the relationship with oxidative DNA damage.

Methods: The study enrolled 162 subjects, 96 with type 2 diabetes and 66 healthy individuals were randomly selected to participate in prospective genotype detection by standard polymerase chain reaction methods and restriction fragment length polymorphism (PCR-RFLP). The polymorphism of FokI and BsmI genes and its association with DNA damage were determined. The main outcome measures were oxidative DNA damage marker including serum 8-hydroxy 2-deoxy guanosine (8-OHdG) and 25 hydroxy vitamin D [25(OH) D].

Results: Notable statistical significance exists in the frequency of genotype and allele of FokI (VDR 2228570 C>T) in patient group (OR 9.7, P=0.01) compared with the healthy individual group. No significant difference was found in the patient group (OR 0.74, p=0.66) in the frequency of genotype and allele of BsmI (VDR 1544410 A>G.). The frequency allele carrier of the (VDR 2228570) C allele was higher in the patients sub- group with high DNA damage than in the healthy individuals (OR=1.22, CI=0.02-18.9, p= 0.70). The frequency allele carrier of the (VDR 1544410) G allele was also higher in the patients sub-group with a high level of DNA damage than in the healthy individuals (OR=1.38, CI=0.13-16.8, p=0.57).

Conclusion: Our results suggest a significant relationship between DNA damage and the gene polymorphism FokI (VDR 228570 C>T) CC and its allele C among diabetic patients. Additionally, our results suggest that the high prevalence of FokI (VDR 228570 C>T) polymorphism among patients group may be a genetic marker of susceptibility for diabetes in our population.

Duhok Med J 2019; 13 (2): 9-19.

Keywords: 8-OHdG, FokI gene, BsmI gene, Vitamin D receptor gene, vitamin D deficiency, Type 2 diabetes.

Patients with type 2 diabetes mellitus and vitamin D deficiency promote a great intensive to study the extent of DNA damage and factors affecting this health problem in the community. Vitamin D is involved in DNA damage as well as in

DNA repair and found to be a potential contributing cause of many diseases^{1,2}. Adequate levels of vitamin D may be beneficial in maintaining DNA integrity³, whereas its deficiency may increase DNA damage⁴. In addition, much is known

* Assistant lecturer in Medical Lab. Technology, Technical Collage of Health/ Shekhan, Duhok Polytechnic University, Duhok, Kurdistan Region, Iraq.

* *Professor, Department of Medical Chemistry, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

Correspondence author to: Dhia J.Al-Timimi, altmimidi@yahoo.com, Mobil +9647504228908

about the association between vitamin D and oxidative stress in cell culture and animal studies⁵.

There is a general agreement that strand breaks in DNA and base modification is caused by reactive oxygen species (ROS), through activate nuclear transcription factor (NF)- κ B,, including oxidation of guanine residues (most potential base in DNA molecule) to 8-hydroxy-2'deoxyguanosine (8-OHdG), a marker that is frequently detected and studied DNA damage in tissue⁶.

It has been shown that vitamin D is essential in maintaining genome stability and inadequate vitamin D is associated with increased frequencies of chromosomal aberrations DNA strand break and other metabolic abnormalities⁷.

Numerous polymorphisms of VDR genes have been identified at chromosome 12q113.1, of these FokI (T/C rs2228570), BsmI (G/A rs 1544410), ApaI (G/T rs7975232), and TaqI (T/C rs731236) which are located in exon 2, intron 8, and exon 9, respectively. These genes may have an influence on insulin secretion and sensitivity⁸.

Vitamin D/Vitamin D receptor associations may in turn negatively impact patient diabetes and result in frequent DNA damage⁹. Although some studies have identified positive effects of vitamin D intake on levels of DNA damage⁴, little research has been demonstrated the association between VDR polymorphisms with the risk of DNA damage.

The purpose of this study isto identify vitamin D receptor genotypes among Kurd patients with type 2 diabetes and healthy subjects, as well as identify the relationship with DNA damage.

METHODS

The study was conducted in Duhok Diabetes Center, Duhok, Kurdistan Region, Iraq; between October 2017 and May 2018. The medical ethics committee of Duhok College of Medicine and Duhok General Directory of Health approved the study, and informed consent was obtained from all participants. Participants were instructed to visit the Lab-Department of Clinical Biochemistry at Azadi Teaching Hospital; controls were also instructed to attend the same place in the morning after overnight fasting for 12-14 hours.

Blood samples were collected, and the sera were separated by centrifugation using a HITACHI centrifuge (model O5P-21) at 5000 rpm for 10 minutes and collected into two tubes, one processed immediately for measuring serum 25(OH) D using clinical chemistry analyzer Cobas 6000 Roche (open, automated, discrete and random access) and the latest liquid sera were stored at -80°C for later analysis of 8-OHdG. Measurement of 8-OHdG was done using ELISA technique. The Iranpur and Esmailzadeh (2010), the method was used for extracting DNA from the whole blood; The DNA samples were checked for concentration and quality using the Nano-Drop 2000 Spectrophotometer for the amplification of the region of interest of the VDR gene (FokI, BsmI)¹⁰.

Two Sets primers manufactured by macrogen (South Korean) and supplied lyophilized were used. Each primer stock was re-suspended in a designated volume of DW to give a final concentration of 100 pmol/ul. Agarose gel was prepared in a concentration of 2% for PCR-RFLP product of the amplified and digested amplicon.

Assessment of DNA damage based on 8-OHdG levels, a cutoff point of > 4.0 ng/ml considered high DNA damage. A cutoff

point of less than 20 ng/ml of 25(OH) D was considered a low vitamin D status.

STATISTICAL ANALYSIS:

All data were analyzed using the Statistical Package for Social Science SPSS version 18.0 computer software. Significance of association between various risk factors for categorical data was assessed by using Chi-square test for association between two groups and one way ANOVA test for association among more than two groups.

RESULTS

The sample size of 162 subjects with 1.5:1 patient: healthy subject ratio results in statistical power of >90%. The overall genotype error rate between the duplicate was 1.8%. The PCR implication product of FokI gene, if the digested generate a 265 bp fragment, it is a homozygous, genotype CC (FF). If 3 fragments of 265bp, 196 bp and 69bp, it is heterozygous, the genotype is TC (fF). If there is 196-69 bp fragment, it is homogenous genotype TT (ff) (Figure 1). Regarding the BsmI gene, if the digested generate an 825 bp fragment, it is a homozygous genotype AA (BB).




Figure 2: The Digested Results Electrophoresis (PCR-RFLP analysis of VDR gene, FokI Polymorphism on 2% Agarose Gel.)

If 2 fragments of 825 bp, 650 bp and 175 bp, it is a heterozygous genotype AG (Bb). If there is 650 bp and 175 bp Fragments, it is homogenous genotype GG (bb) (Figure2).




Figure 2: The Digested Results Electrophoresis (PCR-RFLP analysis of VDR Gene, BsmI Polymorphism on 2% Agarose Gel.)

The frequency of VDR (FokI) gene in diabetic patients and healthy subjects are present in Table 1.

Table 1: FokI (VDR 2228570 C>T) Genotype and Allele Frequency in Diabetic Patients and Healthy Individuals

Genotype FOKI	Patients n(%)	Healthy individuals n(%)	OR	95% CI	p-value
CC	22 (22.9)	2 (3.1)	9.7	1.18-79.6	0.01
TC*	68 (70.8)	60 (90.9)	-	-	-
TT	6 (6.3)	4 (6.0)	1.32	0.2-8.4	0.76
<i>P-value</i>	0.04				
<i>X²</i>	6.22				
Alleles					
C	112(58.3)	64(48.5)	1.49	1.0-29.9	0.37
T	80(41.7)	68(51.5)	0.67	0.15-13.08	0.55
** <i>P-value</i>	0.02	0.73			

VITAMIN D RECEPTORS GENES POLYMORPHISMS AND OXIDATIVE DNA

The most prominent allele in the patients group was C 56(58.3%) compared to T allele 40(41.7%), P= 0.02. The frequency CI=1.0-29.9, P=0.37). Analysis of FokI genotype frequency distribution among study subjects also revealed that the (VDR 228570 C>T) CC was the most prominent in the patients group compared with that of TT, 22 (22.9%) vs. 6 (6.3%), P=0.04. The CC genotype was significantly more frequent in the patients group than in healthy subjects (OR= 9.70, CI=1.18-79.6, P=0.01). Healthy subjects group, FokI

allele carrier of the (VDR 228570 C>T) C allele was higher in the patients group than in the healthy subjects (OR=1.49, genotype distribution frequency observations CC, TC, TT was 2(3.1%), 60 (90.9%) and 4 (6.0%).

The differences between diabetic patients and healthy subjects regarding to the frequency of the BsmI genotype and allele did not show statistical significance (Table2).

Table 2: BsmI (VDR 1544410 A>G) Genotype and Allele Frequency in Diabetic Patients and Healthy Individuals

Genotype BsmI	Patients n(%)	Healthy individuals n(%)	OR	95%CI	p-value
AA	24(25.0)	22 (33.3)	0.74	0.45-14.8	0.66
GA	38(39.6)	26 (39.4)	–	–	–
GG	34(35.4)	18(27.3)	1.29	0.46-9.5	0.68
P-value	0.64				
X ²	0.88				
Alleles					
A	86(44.8)	70(53.0)	0.72	0.1-15.3	0.47
G	106(55.2)	62(47.0)	1.39	0.5-15.4	0.47
P-value	0.15	0.49			

The most prominent allele in the patients group was G 106 (55.2%) compared to A allele 86 (44.8%), P=0.15. The frequency allele carrier of the (VDR 1544410A>G) G allele was higher in the patient's group than in the healthy subjects (OR 1.39, CI=0.5-15.4, P=0.47). Analysis of GG genotype distribution among study subjects also revealed that the (VDR 1544410 A>G) GG was the most prominent in the patients group compared with that of AA, 34 (35.4%) vs. 24 (25%), P=0.64. Healthy subject group BsmI genotype distribution frequency observations AA, AG, GG were 22 (33.3%), 26 (39.4%) and 18 (27.3%). The

GG genotype was more frequent in the patients group than in healthy subjects (OR=1.29, CI=0.49-9.5, P=0.68).

The allele and genotype frequency of FokI gene in diabetic patients and healthy subjects with high DNA damage are present in Table 3.

Table 3: FokI (VDR 2228570 C>T) Genotype and Allele frequency in Diabetic Patients and Healthy Individuals with High DNA Damage.

Genotype FokI	Patients n(%)	Healthy individuals n(%)	8-OHd OR	G ≥ 4.0 95%CI	ng/ml p-value
CC	20(21.7)	2(5.3)	5.45	0.01-27.7	0.71
TC	66(71.7)	36(94.7)	–	–	–
TT	6(6.6)	0(0.0)	–	–	–
<i>P-value</i>	0.11				
<i>X²</i>	4.30				
Alleles					
C	106(57.6)	40(52.6)	1.22	0.02-18.9	0.70
T	78(42.3)	36(47.4)	0.82	0.59-10.7	0.72
<i>P-value</i>	0.15	0.73			

The frequency allele carrier of the VDR 2228570 (C allele) was higher in the patients sub-group with high DNA damage than in the healthy subjects (OR=1.22, CI=0.02-18.9, P= 0.70). The most prominent allele in the patients sub-group with high DNA damage was C, 106 (57.6%) compared to T allele 78 (42.3%), P=0.15. Analysis of FokI genotype frequency distribution among sub-groups also revealed that the VDR 228570 CC was the most prominent in patients

compared with that of TT, 20 (21.7%) vs 6 (6.6%), P=0.11.

The most prominent allele in the diabetic patients sub-group with high DNA damage was G 102 (55.5%) compared to A allele 82 (44.5%), P=0.92 (Table 4).

Table 4: BsmI (VDR 1544419 A>G) Genotype and Allele Frequency in Diabetic Patients and Healthy Individuals with High DNA Damage.

Genotype	Patients n (%)	Healthy individuals n (%)	BsmI 8-OHd n(%)	G ≥ 4.0 OR95%CI	ng/ml p-value
AA	22(24.0)	10(26.3)	0.86	0.60-13.4	0.92
AG	38(41.2)	20(52.6)			
GG	32(34.8)	8(21.1)	2.10	0.81-7.80	0.61
<i>P-value</i>	0.54				
<i>X²</i>	1.24				
Alleles					
A	82(44.5)	40(52.5)	0.72	0.37-15.7	0.56
G	102(55.5)	36(47.5)	1.38	0.13-16.8	0.57
<i>P-value</i>	0.92	0.75			

The frequency allele carrier of the (VDR 1544410) G allele was higher in the patient sub-group with high DNA damage than in the healthy subjects (OR=1.38, CI=0.13-16.8, P=0.57). Analysis of BsmI genotype frequency distribution among sub-groups also revealed that the VDR 1544410 GG was the most prominent in patients

compared with that of AA, 32 (34.8%) vs. 22 (24.0%), P=0.54.

For FokI polymorphism, in vitamin-D sub-group of patients, the CC genotype frequency was quite a bit higher in comparison with that of the healthy individual group, however, the increase

VITAMIN D RECEPTORS GENES POLYMORPHISMS AND OXIDATIVE DNA

was not statistically significant (OR=3.17, CI=0.05-1.9, P=0.18) (Table 5).

Table 5: FokI (VDR 2228570 C>T) Genotype and Allele Frequency in Diabetic Patients and Healthy Individuals with Low Vitamin D Status

Genotype	Patients	Healthy individuals 25(OH)D < 20ng/ml			
		n(%)	n(%)	OR95%CI	p-value
CC	8(16.7)	2(6.25)	3.17	0.05-1.9	0.81
TC	36(75.0)	28(87.5)			
TT	4(8.3)	2(6.25)	1.58	0.09-5.16	0.95
<i>P-value</i>	0.55				
X^2	1.08				
Alleles					
C	52(54.2)	32(50.0)	1.18	0.46-8.2	0.79
T	44(45.8)	32(50.0)	0.84	0.42-8.0	0.80
<i>P-value</i>	0.55	1.0			

There was none significant difference between patients with C>T and healthy subjects in the frequency of C and T allele (P=0.8). For VDR 1544410 A>G polymorphism, we observed that there was

a significant difference between the low vitamin D sub-group in diabetic patients and healthy subjects (P=0.01) (Table 6).

Table 6. BsmI (VDR 1544419 A>G) genotype and allele frequency in diabetic patients and healthy individuals with low vitamin D status.

Genotype	Patients	Healthy individuals 25(OH)D < 20 ng/ml			
		n(%)	n(%)	OR95%CI	p-value
AA	6(12.5)	8(25.0)	0.67	0.8-14.8	0.70
AG	18(37.5)	16(50.0)			
GG	24(50.0)	8(25.0)	2.67	0.24-31.0	0.39
<i>P-value</i>	0.26				
X^2	2.71				
Alleles					
A	30(31.2)	32(50.0)	0.45	0.6-31.8	0.29
G	66(68.8)	32(50.0)	2.20	0.03-34.4	0.20
<i>P-value</i>	0.01	1.0			

DISCUSSION

This study is the first to examine the association of vitamin D receptor (VDR) gene polymorphism with DNA damage in Duhok population. Vitamin D receptors are widely distributed in human tissues, which is controlled vital genes related to bone metabolism, oxidative damage and chronic inflammatory diseases¹¹. Vitamin D/ vitamin D receptors also play a role in regulating the B-cell insulin secretion¹². Several polymorphisms, such as BsmI (VDR1544410A>G) and FokI (VDR 2228570 C>T), have been described in the VDR genes that are able to alter the

activity of VDR protein¹³. It has been demonstrated that BsmI and FokI polymorphisms are associated with type 2 diabetes mellitus, insulin secretion¹⁴ and with metabolic changes related to obesity and oxidative damage¹⁵. Although the link between vitamin D deficiency and DNA damage has been previously demonstrated¹⁶, few studies have examined VDR gene polymorphisms and its association with the risk of DNA damage¹⁷. Thus, this study was conducted to examine the polymorphism of VDR gene (FokI and BsmI) in type 2 diabetic patients and healthy subjects.

More ever, we intended to investigate the association of VDR gene polymorphism [FokI (VDR 228570 C>T), BsmI (VDR1544410A>G)] with the level of DNA damage in type 2 diabetic patients and healthy subjects.

The present study demonstrates the genetic contribution of VDR gene polymorphisms for diabetes. The study found that the frequency of FokI 228570 CC genotype was significantly higher in the group of diabetes than in a healthy group and confirmed a significant relationship between polymorphism of VDR 228570 CC genotype and allele C with DNA damage. Further, the frequency of BsmI genotype and allele did not show significant differences between diabetic and healthy group. This was consistent with other studies¹⁸. In a study from Saudi Arabia, it has been reported that no association was noticed between VDR BsmI polymorphism and gestational diabetes mellitus in the Saudi population. The gene frequency, allele frequency and carriage rate of the VDR polymorphism BsmI did not differ between patients and controls with no significant association with any clinical parameters¹⁹.

Similarly, to that reported in the previous study conducted in type 2 diabetic Egyptian patients, we found that the frequency allele carrier of the VDR 228570 (C allele) was higher in diabetic patients with high level of DNA damage than in healthy subjects, but the frequency of the BsmI genotype and allele did not show any significant differences between the two groups²⁰. Vitamin D receptor (VDR) gene variants may contribute to the development of diabetes mellitus. Ban Y, et al, have

reported that BsmI increased susceptibility for type 1 diabetes²¹. In contrast, our results did not showed any significant differences between patients group and healthy individuals. However, analysis of genotype frequency distribution among the studied subjects revealed that the (VDR 228570 C>T) CC was the most prominent one for FokI and (VDR1544410A>G) GG for BSMI and both were more frequent in the patients group than in healthy individuals. In this study we found that the genotypes and their combinations in alleles may confer increased susceptibility to diabetes in association with increased DNA damage.

CONCLUSIONS

Our results suggest a significant relationship between DNA damage and the gene polymorphism FokI (VDR 228570 C>T) CC and its allele C among diabetic patients. Additionally, our results suggest that the high prevalence of FokI (VDR 228570 C>T) polymorphism among patients group may be a genetic marker of susceptibility for diabetes in our population.

ACKNOWLEDGEMENT

We acknowledge the support of Duhok Diabetes Center, Azadi Teaching Hospital who provided the facilities for the interviews and the laboratory work.

REFERENCES

1. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, et al. Vitamin D and risk of cause specific death: systematic

review and meta-analysis of observational cohort and randomised intervention studies. *BMJ*. 2014; 348:g1903.

2. Al-Timimi DJ, Hazim SH, Ahmed IH. Vitamin D status and metabolic abnormality profile among siblings of patients with type 2 diabetes mellitus. *Duhok Med J*. 2015; 9(2):1-9.

3. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. *Annals of epidemiology*. 2009; 19(7):468-83.

4. Nair-Shalliker V, Armstrong BK, Fenech M. Does vitamin D protect against DNA damage? *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 2012; 733(1-2): 50-7.

5. Wang EW, Collins AR, Pang MY, Siu PP, Lai CK, Woo J, et al. Vitamin D and oxidation-induced DNA damage: is there a connection? *Mutagenesis*. 2016; 31(6):655-9.

6. Nishikawa M. Reactive oxygen species in tumor metastasis. *Cancer letters*. 2008; 266(1):53-9.

7. Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY, Glodzik D, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. *Journal of Clinical Oncology*. 2014; 32(23): 2430-9.

8. Alvarez JA, Ashraf AP, Hunter GR, Gower BA. Serum 25-hydroxyvitamin D and parathyroid hormone are independent determinants of whole-body insulin sensitivity in women and may contribute to lower insulin sensitivity in African Americans. *The American journal of clinical nutrition*. 2010; 92(6): 1344-9.

9. Graziano S, Johnston R, Deng O, Zhang J, Gonzalo S. Vitamin D/vitamin D

receptor axis regulates DNA repair during oncogene-induced senescence. *Oncogene*. 2016; 35(41): 5362.

10. Iranpur M, Esmailzadeh A, Horriat R, Asadi K, Shiran B, Sorkheh K, et al. Rapid extraction of high quality DNA from whole blood stored at 4°C for long period. 2012.

11. Brożyna AA, Jozwicki W, Janjetovic Z, Slominski AT. Expression of vitamin D receptor decreases during progression of pigmented skin lesions. *Human pathology*. 2011; 42(5): 618-31.

12. Filus A, Trzmiel A, Kuliczowska-Płaksej J, Tworowska U, Jędrzejuk D, Milewicz A, et al. Relationship between vitamin D receptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome. *The Aging Male*. 2008; 11(3): 134-9.

13. Sung C-C, Liao M-T, Lu K-C, Wu C-C. Role of vitamin D in insulin resistance. *BioMed Research International*. 2012; 2012.

14. Ye W-Z, Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. *European Journal of Endocrinology*. 2001; 145(2):181-6.

15. Oh J-Y, Barrett-Connor E. Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study. *Metabolism-Clinical and Experimental*. 2002; 51(3): 356-9.

16. Narvaez CJ, Matthews D, Broun E, Chan M, Welsh J. Lean phenotype and resistance to diet-induced obesity in

vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. *Endocrinology*. 2009; 150(2): 651-61.

17. Fedirko V, Bostick RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. *Cancer Epidemiology and Prevention Biomarkers* .2010; 19(1): 280-91.

18. Elhusseini H, Elkafas H, Abdelaziz M, Halder S, Atabekov I, Eziba N, et al. Diet-induced vitamin D deficiency triggers inflammation and DNA damage profile in murine myometrium. *International journal of women's health* .2018; 10:503.

19. Tawfeek M. Vitamin D receptor BsmI gene polymorphisms and gestational diabetes mellitus: a Saudi study. 2011.

20. Mackawy AM, Badawi ME. Association of vitamin D and vitamin D receptor gene polymorphisms with chronic inflammation, insulin resistance and metabolic syndrome components in type 2 diabetic Egyptian patients. *Meta gene* 2014; 2: 540-56.

21. Ban Y, Taniyama M, Yanagawa T, Yamada S, Maruyama T, Kasuga A, et al. Vitamin D receptor initiation codon polymorphism influences genetic susceptibility to type 1 diabetes mellitus in the Japanese population. *BMC Medical Genetics* .2001; 2(1): 7.

ثوخته

وهرطرين ظيتامين (د) و زراري DNA لدهف نهخوشين كورد بين شكري ذجوري دووي

نیشةکی: ستره رای کو نهیوهندی دناظ بهرا زرارا DNA و ظيتامين (د) هاتیه خواندن بهری نوکه. کیم طهکولينا تشکينا جورين جيني بين وهرطرين ظيتامين (د) کرية نو نهیوهنين وي دطلمهترسيا زراروبونا DNA. نارمانجا طي طهکوليني نهوه بو دهستنيشانکرنا جورين جيني بين ظيتامين (د) لدهف نهخوشين شكري ذجوري دووي و نهیوهنديين وي دطل زراروبونا DNA.

ريکين طهکوليني: طي طهکوليني 162 کس بخوطة طرفن دوانا 96 کسا نيشا شكري هتوبو ذجوري دووي و 66 کس دساخلم بوون هاتبونه ههليدارتن بشيوهيهکی سترهخو بو بهشداريکردن دطي طهکولينيذا ذبو ديتنا جورين جيني بريکا (PCR-RFLP). ههمه جوريا جيني هاتنه دهستنيشانکرن و نهیوهنديين وي دطل زراروبونا DNA. نيهترين دهر نهناجمين سترهکی دطي طهکولينيذا هيمايي زراروبونا DNA بخوطة طرفنو (8-OHdG) دطل ناستي ظيتامين (د) دناظا خوينيذا (OH)D (25).

نهجام: ريذا بهربهلاظبونا جورين جيني و نهليلي (C>T) rs2228570 بشيوهکی بهرضاظ هاته ديتن لدهف نهخوشين شکر نههموارکردن دطل مروضين ساخلم (OR 9.7, P=0.01) بهلي جياوازي نه بشيوهيهکی بهرضاظو ستهارهت ريذا بهربهلاظبونا جورين جيني و نهليلي (A>G) rs1544410. ريذا بهربهلاظبونا ههلهطري جورين جيني و نهليلي (C) rs2228570 نتر بوو لدهف نهخوشين شكري بين ريذا زرارا DNA ياوان يا بلند ههموارکردن دطل کتسين ساخلم (OR=1.22, CI=0.02-18.9, p= 0.70). ريذا بهربهلاظبونا ههلهطري جورين جيني و نهليلي (G) rs1544410 ديسان نتر بوو لدهف نهخوشين شكري بين ريذا زرارا DNA ياوان يا بلند ههموارکردن دطل کتسين ساخلم (OR=1.38, CI=0.13-16.8, p=0.57).

دهر نهجام: نهجامين طهکولينا نه نيشنيار دکته کو نهیوهنديکا بهرضاف يا هه دناظ بهرا زراروبونا DNA و هههونا جورين جيني بين جور و جور CC (C>T) rs2228570 و نهليلي وي (c) لدهف نهخوشين شکر ههه. ديسان, نهجامين طهکولينا نه نيشنيار دکته کو بلنديونا ريذا بهربهلاظبونا جورين جيني و نهليلي rs2228570 (C>T) لدهف نهخوشين شکر ههه هيمايهکی متهر سيداري جيني بو توشبون ب نهخوشيا شكري لدهف هاولاتيان ل دهظهنامه.

الخلاصة

مستقبلات فيتامين (د) والتلف التأكسدي للحمض النووي لدى الكورد المصابين بمرض السكري من النوع الثاني في اقليم كردستان العراق

الهدف: على الرغم من ان العلاقة بين فيتامين (د) والتلف التأكسدي للحمض النووي تم دراستها سابقاً، قلة من الدراسات فحصت تعدد اشكال الجينات لمستقبلات فيتامين (د) وعلاقتها مع خطورة تلف الحمض النووي. هدفت هذه الدراسة إلى تحديد الأنماط الوراثية لمستقبلات فيتامين (د) لدى مرضى السكري من النوع الثاني والاشخاص الاصحاء وتحديد علاقتها مع التلف التأكسدي للحمض النووي.

طرق البحث: تضمنت هذه الدراسة 162 شخصاً، 96 منهم مرضى لديهم مرض السكري من النوع الثاني و66 اشخاص أصحاء تم اختيارهم عشوائياً للمشاركة في هذه الدراسة المحتملية لاكتشاف تعدد الجينات بطريقة (PCR-RFLP). تم تحديد تعدد أشكال الجينات rs1544410 و rs2228570 وعلاقتها مع التلف التأكسدي للحمض النووي بمقاييس النتائج الرئيسية تضمنت مؤشر التلف التأكسدي للحمض النووي (8-OHdG) ومستوى فيتامين (د) في الدم [D (OH) 25].

النتائج: وجدت نسبة انتشار الشكل الجيني والليل (C>T) rs2228570 بشكل ملحوظ احصائياً في مجموعة المرضى مقارنة بمجموعة الاشخاص الاصحاء (OR 9.7, P=0.01) لكن الاختلاف لم يكن ملحوظاً إحصائياً بالنسبة لنسبة انتشار الشكل الجيني والليل (A>G) rs1544410. نسبة انتشار حامل الليل rs2228570C كان أعلى في مجموعة المرضى الذين لديهم تلف الحمض النووي عالي مقارنة مع الاشخاص الاصحاء (OR=1.22, CI=0.02-18.9, p=) (0.70). نسبة انتشار حامل الليل (G) rs1544410 كان أيضاً أعلى في مجموعة المرضى الذين لديهم تلف الحمض النووي عالي مقارنة مع الاشخاص الاصحاء (OR=1.38, CI=0.13-16.8, p=0.57).

الاستنتاج: نتائجنا اقترحت بأن هناك علاقة ملحوظة بين تلف الحمض النووي وتعدد الاشكال الوراثي للجينات (C>T) rs2228570 والليلها (c) لدى مرضى السكري. إضافة إلى ذلك اقترحت أيضاً نتائجنا بأن نسبة الانتشار العالية لتعدد الشكل الجيني (C>T) rs2228570 لدى مرضى السكري قد يكون عامل خطورة وراثي لاحتمالية الاصابة بالسكري في المجتمع.